<?xml version="1.0" encoding="UTF-8"?>
<p>Oral pre-exposure prophylaxis (PrEP) for HIV—in the form of co-formulated tenofovir (TDF) and emtricitabine (FTC)—has been studied extensively, shown to reduce HIV acquisition in women [
 <xref rid="pone.0223487.ref006" ref-type="bibr">6</xref>, 
 <xref rid="pone.0223487.ref007" ref-type="bibr">7</xref>], and to be safe for mothers and infants [
 <xref rid="pone.0223487.ref008" ref-type="bibr">8</xref>]. In PrEP studies among HIV-serodiscordant couples, early evidence on birth outcomes and infant growth has been reassuring [
 <xref rid="pone.0223487.ref009" ref-type="bibr">9</xref>–
 <xref rid="pone.0223487.ref011" ref-type="bibr">11</xref>]. PrEP during pregnancy and breastfeeding is also cost-effective in settings where HIV incidence is high [
 <xref rid="pone.0223487.ref012" ref-type="bibr">12</xref>]. In women, daily adherence is critical to its effectiveness. In studies where adherence was high, the risk for new HIV infections dropped by as much as 85% [
 <xref rid="pone.0223487.ref006" ref-type="bibr">6</xref>]; in studies demonstrating low adherence, results were equivocal [
 <xref rid="pone.0223487.ref013" ref-type="bibr">13</xref>].
</p>
